Taysha Gene Therapies (TSHA) Other Accumulated Expenses (2019 - 2026)

Taysha Gene Therapies has reported Other Accumulated Expenses for 8 years, with the latest figure at $784000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses fell 2.73% year-over-year to $784000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $784000.0 (down 2.73% YoY) and the FY2025 annual result came in at $777000.0, up 3.32% from the prior year.
• Other Accumulated Expenses advanced to $784000.0 in Q1 2026 per TSHA's latest filing, from $777000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $1.6 million in Q1 2022 and troughed at $650000.0 in Q4 2022.
• A 5-year average of $892588.2 and a median of $777000.0 in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses soared 1139.06% in 2022, then sank 56.9% in 2023.
• Over 5 years, Other Accumulated Expenses stood at $650000.0 in 2022, then increased by 11.23% to $723000.0 in 2023, then climbed by 4.01% to $752000.0 in 2024, then advanced by 3.32% to $777000.0 in 2025, then increased by 0.9% to $784000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $784000.0, $777000.0, and $749000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.